Form 4: Halozyme CEO Helen Torley Trades Shares

Halozyme Therapeutics President and CEO Helen Torley executed a series of stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• Helen Torley, President and CEO of Halozyme Therapeutics, Inc., reported transactions involving the company's common stock on April 1st and 2nd, 2026.
• These transactions included the exercise of stock options and the subsequent sale of shares.
• The option exercises occurred at a price of $12.07 per share.
• Sales of common stock were conducted at weighted average prices ranging from $63.650 to $65.860 per share.
• All transactions were executed under a written trading plan adopted on March 21, 2025, in accordance with Rule 10b5-1, which is intended to satisfy affirmative defense conditions for insider trading.
• Following these transactions, Torley's beneficial ownership of common stock was reported as 767,780 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by the CEO could be seen negatively, the adherence to a pre-established 10b5-1 plan mitigates concerns about insider trading and suggests a planned divestment rather than a reaction to negative non-public information.

Positives

• Transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive activity.
• The CEO continues to hold a significant number of shares (767,780) after the reported transactions, suggesting continued commitment to the company.

Negatives

• A substantial number of shares were sold by the CEO, which could be perceived negatively by the market, despite being part of a pre-planned strategy.
• The exercise of options and immediate sale of shares, even under a 10b5-1 plan, represents a divestment of equity.

Risks

• The sale of a significant number of shares by a key executive, even under a 10b5-1 plan, could be interpreted by the market as a lack of confidence or a signal of potential future price declines.
• While the plan is designed to mitigate insider trading concerns, the sheer volume of shares sold might still raise questions among investors about the executive's personal outlook on the company's stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1.
• The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
• The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by Halozyme's CEO is a common practice to allow executives to trade company stock systematically while avoiding concerns about insider trading, especially during periods of significant company news or market volatility.

Stakeholder Impact

• Shareholders: May observe the CEO's stock sales, potentially leading to short-term sentiment shifts, though the 10b5-1 plan provides a framework for understanding these transactions.
• Employees: May interpret the CEO's sales as a signal, though the pre-planned nature of the trades should be considered.
• Management: The CEO's actions are within established corporate governance protocols for insider trading compliance.

Next Steps

• The reporting person will continue to adhere to the Rule 10b5-1 trading plan.
• Information regarding specific sale prices will be provided to the issuer, security holders, or SEC staff upon request.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Share Sales, 10b5-1 Plan, Halozyme Therapeutics, HALO, Executive Transactions, Beneficial Ownership